Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Marijuana Stocks Thursday Evening Recap - $ICNAF
https://marijuanastocks.com/marijuana-stocks-thursday-evening-recap-september-20-2018/
3 Tech Stocks Profiting From Billion Dollar, On-Demand Boom
$PTNYF $PKG
https://medium.com/stock-market-source/3-tech-stocks-profiting-from-billion-dollar-on-demand-industry-cfbc5d2228d8
$PTNYF ParcelPal Commences National Expansion Starting in Alberta
https://ca.finance.yahoo.com/news/parcelpal-expands-calgary-120000272.html
VANCOUVER, BC / ACCESSWIRE / September 18, 2018 / ParcelPal Technology Inc. ("ParcelPal" or the "Company"), (PKG.CN) (PT0.F) (OTC PINK: PTNYF) - is pleased to announce they have commenced their national rollout plan starting with the much-anticipated expansion into Calgary, Alberta.
ParcelPal is looking to exponentially grow its business and make mobile on-demand deliveries a widespread service throughout cities across Canada. The Company has been operating successfully in Vancouver for over a year and is now expanding to Calgary as part of their on-going strategy for Canada wide distribution.
ParcelPal will be launching with all verticals offered (Food, alcohol, grocery, and soon 'Get Anything') on their platform, on both Android and iOS. The Company is in late-stage planning for implementation of marijuana delivery in the province of Alberta. Comparable to Vancouver, Calgary offers a diverse population of over 1.5 million residents within the initial operational zone. With similar demographics to Vancouver, the Company expects rapid adoption of the service.
The Company has secured an office in Calgary and is currently onboarding all key personnel to fill all necessary roles for the launch. The Company is actively looking to expand with new and existing partnerships within this region. This should enable the Company to achieve a greater run rate in the coming months.
President and CEO Kelly Abbott states, "We are very pleased to finally offer ParcelPal services residents of Calgary. We are excited by the opportunity that Calgary presents. We feel this expansion to Calgary will bring great shareholder value and this launch will be the cornerstone for all expansions moving forward. Our increased investments in technology, brand and delivery are on track to make our service even easier to use, whilst expanding our customer's choices. I'm pleased with the strong results of the year and excited by our opportunity for accelerated growth across Canada."
ParcelPal's City Manager Alain Duperes states, "We are excited to be a part of the vibrancy and energy of Calgary and its residents and to welcome a whole new dynamic of on-demand delivery. This will now allow residents to get what they want or need, delivered within an hour or less which is greatly needed."
Calgary residents can download the app by visiting www.parcelpal.com or by visiting the App Store on their mobile devices.
$ICNAF Prepare For A Boom In Pot Stocks
https://marijuanastocks.com/prepare-for-a-boom-in-pot-stocks/
$PTNFY $PKG ParcelPal talks cannabis plan for Oct. 17 legalization
https://www.stockwatch.com/News/Item.aspx?bid=Z-C%3aPKG-2658675&symbol=PKG®ion=C
PKG NEWS RELEASE - PARCELPAL ANNOUNCES MARIJUANA STRATEGY
ParcelPal Technology Inc. has provided further insight into its cannabis plan for federal legalization in Canada on Oct. 17, 2018.
As part of ParcelPal's strategy moving forward, the company plans to take advantage of the bourgeoning marijuana market imminently. The marijuana vertical proposes a large opportunity and catalyst for ParcelPal to launch into many urban areas across Canada. The company has been speaking with provincial government regulators and Crown corporations to best assess how to implement and execute on its strategy going forward with recreational and medicinal marijuana. Additionally, the company has been speaking with major licensed producers to ensure a supply and consistent demand to ensure a smooth execution into the industry.
For consumers, taking advantage of ParcelPal's service provides many benefits, such as:
Quick delivery -- getting their cannabis products/ancillaries delivered in an hour or less;
Anonymity -- not having to visit a retail location and remaining anonymous;
Mitigating intoxication -- no longer having to leave the house, mitigating the risk of driving while intoxicated;
The ability to service both medicinal as well as recreational users.
Customers who order marijuana through the ParcelPal platform will be required to upload and verify their identities. Users that are under the age within their jurisdictions will not be allowed into this vertical on the application. The identity verification system ensures that the person is of age and that the identity is in fact real, and it is checked twice -- once before and once upon delivery. Consumers who order product will have to be the person to receive the order. ParcelPal's technology complies with all local, provincial and federal laws.
Additionally, ParcelPal's cannabis vertical helps major licensed producers and other suppliers of cannabis products with the following:
Easy access to consumers, providing an omnichannel approach to sales and distribution;
Quick delivery -- the ability to deliver cannabis products within an hour allows for immediate gratification for consumers; something others currently cannot provide;
Compliance with regulatory framework;
Management team and board familiar with regulatory environments for a quick path to implementation;
Increase business between existing players in the cannabis industry;
Uninterrupted services, without strikes.
President and chief executive officer Kelly Abbott stated: "This is a critical time for the cannabis industry as a whole. Adult recreational use is on the precipice of becoming legal across Canada and we are poised to take advantage of the ancillary market yet to come. We are setting a standard in Canada for accessibility, safety and professionalism." Mr. Abbott continued, "I believe attention from the investment community will shift from production to those who are supporting production and all things distribution."
The company's reach will enable access to data and further insights into patient and user demographics, preferences, behaviours and patterns. ParcelPal plans on utilizing its delivery data to educate and inform regulators and licensed producers; this is essential for ensuring continued safe access for everyone within the industry.
Marijuana Stocks Connecting The Dots: New Opportunity Ahead for This CBD Company
https://marijuanastocks.com/marijuana-stocks-connecting-the-dots-new-opportunity-ahead-for-this-cbd-company/
3 catalysts identified in NR
“We are currently in the late stages of reviewing a short list of potential acquisition opportunities that would broaden our product offering from the existing X-SPRAYS™ line to potentially licensed Cannabis formulations in several US States,”
With market testing complete, X-SPRAYS™ plans to roll out additional brick and mortar distribution throughout dispensaries, vape stores, gas stations, and convenience stores across the country.
the Company intends to launch an aggressive online marketing campaign to drive sales through the utilization of traditional on-line channels and via established product influencers.
Integrated Cannabis Company, Inc. Provides Corporate Update
https://finance.yahoo.com/news/integrated-cannabis-company-inc-provides-120000451.html
New IMTV catalyst posted
https://catalystwire.com/Catalysts/imtv-0003/
Mr. Jim Hutchens reports
IMAGIN MEDICAL REPORTS RESEARCH STUDY PROGRESS
Imagin Medical Inc. has released favourable results in the 10-subject investigator-sponsored research study being conducted at the University of Rochester Medical Center using the i/Blue imaging system (the URMC research study), an important step in the development of a commercially viable product.
In the URMC research study, fluorescence was successfully demonstrated in 15 minutes, confirming that the i/Blue imaging system will potentially allow physicians to see bladder cancer significantly faster than the full hour or more required by currently available imaging technology.
"While a backorder on certain component parts needed to make system adjustments during the URMC research study caused some delay, we are obviously very pleased with the outcome," said Jim Hutchens, Imagin's president and chief executive officer. "This is an exciting time. We believe that the i/Blue imaging system holds great promise for improving physicians' ability to detect cancer and visualize the surgical field where endoscopes are used. To that end, we look forward to updating our stakeholders as we progress."
Information gathered from the URMC research study is being used to help optimize Imagin's i/Blue technology to further the development of a commercially viable device system in preparation for the company's planned clinical trials to support its application to the U.S. Food and Drug Administration (FDA) for approval to market the i/Blue imaging system in the United States.
"Imagin is grateful to the University of Rochester Medical Center for initiating and conducting this investigator-sponsored human research study," commented Pam Papineau, Imagin's director of regulatory and clinical affairs. "Imagin was pleased to provide early prototype equipment to assist the investigators in testing the underlying hypothesis that the i/Blue imaging system can potentially identify protoporphyrin IX (PpIX) fluorescence associated with bladder cancer lesions in the presence of the contrasting agent, hexaminolevulinate hydrochloride. This project was undertaken prior to the commencement of an FDA application and provides important insights that will help guide the company in an FDA-compliant process. Imagin anticipates initiating preliminary discussions with the FDA regarding the i/Blue imaging system as soon as possible."
Running parallel to the URMC research study, the i/Blue imaging system design and development have moved forward, incorporating feedback from the study into the system's opto-electronic functions and features. As previously reported, Optel Inc., Imagin's opto-electronic design firm, is working against three phases of development: proof of concept, functional unit and verified unit. Of the three phases, the proof-of-concept phase has now been completed, verifying the performance of the two critical optical modules of the i/Blue imaging system -- the light source module and the imaging module.
Dr. Jay Eastman, PhD, chief executive officer of Optel, stated: "The lessons learned from the URMC research study has provided valuable technical data, clinical insight and physician feedback that is significantly influencing the design of the i/Blue system. All of this information continues to increase our confidence that the miniaturization, imaging quality and cost reduction goals for the i/Blue system important to surgeons performing bladder cancer procedures."
About Imagin Medical Inc.
Imagin is developing powerful new imaging solutions for the detection and visualization of cancer. The company believes its technology will radically improve physicians' ability to detect cancer with minimally invasive endoscopes, improving their ability to visualize, identify and remove cancerous cells. Imagin's initial target market is bladder cancer, the sixth-most common cancer in the United States and the costliest cancer to treat due to a greater-than-50-per-cent recurrence rate.
CatalystWire is tracking $IMTV and it's Catalysts ! Just need to register it's free.
https://catalystwire.com/imtv/
$IMTV Tweet Looking Forward to the Next Week!
https://twitter.com/ImaginationTVCo/status/1012782425603235840
IMTV Catalysts coming !
https://catalystwire.com/Catalysts/imtv-2/
Looks like Catalyst Wire started posting Catalysts for $IMTV
Interesting free service !!
https://catalystwire.com/
https://catalystwire.com/imtv/
https://twitter.com/ImaginationTVCo/status/1009456293424312321
BUILDING REAL VALUE FOR OUR SHAREHOLDERS is our top priority and the BEST way we know how to do that is building a company that produces growing rev/profit while improving upon the cap structure of $imtv Cont.
TWEET FROM $imtv
https://twitter.com/ImaginationTVCo/status/1009455471080738816
No, we do not need any financing, no we are not looking to dilute. Our focus is building a rev/profit producing business. We are a SUB PENNY STOCK this can mean large fluctuations both up and down. How / Why individual people sell or buy $imtv is not our primary focus. CONT BELOW
Fact is last show IMTV did I didn't know anybody and it was a huge success and profitable. This one will be even bigger. And the word is the next show Aug-Sept has a MEGA STAR !!! Target is set at 3c-5c
Up 6 8 12, down 1. That's the pattern. It's healthy and I'll take it and buy the dips :)
Regardless this is going to multiple pennies by end summer !!
Per company !!
BIG Meeting Today with Nine Mile Entertainment! MAJOR UPDATES & ANNOUNCEMENTS for the "LIT Up Music Festival" Coming VERY Soon!
https://twitter.com/ImaginationTVCo/status/1007678349177753600
I'm hearing the show after this coming one, so (Aug-Sept) could be the 5 cent maker. $IMTV is very very cheap down here.
When (not if) this break all time high it's going to have a life of it's own !! :) Target i heard is 5 cents by fall
Guys I'm hearing 5 cents on this, not sure why traders are messing around with .000's lol Accumulate and Hold is all I can say
Yep these guys are making BIG profits on their events !
http://valueinvestor.com/2018/05/11/block-one-capital-bkppf-blok-v-conference-call/
Great interview with CEO, btw did you guys miss last 5 min of interview...something else in works not mentioned in the transcript....
$BKPPF has millions in CASH in the bank and millions in investments
2 PP's closed $1...
**Current Quarter is between NOW and end June, we are very close...
FINZAT
''In fact, he stated that within the current quarter, the company should be making key deals that the public will hear about (minute 42:16). More specifically he said that he would EXPECT that Finzat would announce new deals within the coming WEEKS''
He also said that when these announcements are made, Finzat will be in a position to raise capital for their growth at a valuation “significantly higher than Block One’s entry point”
SHOPIN (BLOK CEO on board of advisors)
Not only do they receive 66% MORE tokens without having to pay extra but presumably the next round for Shopin could set the tone for its value to be 2.5 to 3.5 times HIGHER than the amount paid by Block One.
Investment opportunity for Imagin Medical’s new bladder cancer detection system
http://www.moneysense.ca/columns/ask-moneysense/investment-opportunity-for-imagin-medicals-new-bladder-cancer-detection-system/
''One of the options the board members are looking at is, if it makes financial sense, to sell to a larger competitor which already has the sales channels and distribution to reach both doctors and patients.''
Good morning, Chris
As I discussed on one of my recent podcasts as well as in a couple of my most recent e-mails, I am glad that--notwithstanding my subdued expectations for stocks generally--I continue to find many a compelling story.
Indeed, in part because of the broad market having bogged down, investors are once again having to actually work to find those strategies and companies that will hopefully outperform the market, if not make LOTS of money.
Thus, in this environment, I expect even more eyes will end up on my newest "story stock," especially as its work towards one of the more transformative technologies in medical devices in a long time continues.
NEW RECOMMENDATION: Imagin Medical (CSE--IME; OTC--IMEXF)
Recent price (Tuesday's close) -- C$0.275 or US$0.216
On the home page of its website, Imagin Medical bills itself as a medical device and--more so--technology company that, ". . .will establish a new standard of care in detecting cancers and visualizing the surgical field in minimally invasive surgery. . ."
As you will be reading below, urologists who have been looking forward to just this kind of breakthrough in efficiency agree; and are putting THEIR OWN money into Imagin!
As I have rolled up my sleeves and come to get to know Imagin better in the recent past (after only cursory looks on a few occasions previously) Imagin--which intends to initially focus on bladder cancer-- seems to have an imaging technology and platform that is at the same time revolutionary . . . yet quite simple and common sense.
As I suspect you already know, surgical practices have advanced tremendously over the years with advances in technology and know-how. For many procedures, it was once common to open up a part of the body--say, an abdomen--and take care of what needed to be done. Among the things this meant was a longer hospital stay and a longer time to recover and heal following such an invasive procedure.
For almost everything, this has been replaced by minimally invasive surgery (MIS.) Advances in optical technology especially have effectively allowed small cameras mounted on endoscopes to be inserted in the area of the body in question; whether to take out cancerous tissue, repair a hernia or what have you. Once the necessary procedure has been identified via the endoscope (which come in many shapes and sizes, but all of which pretty much work on the same principles) the procedure can also be accomplished more simply than in the past. Sometimes, surgical and related instruments can use the same smaller opening the endoscope did; after all, the need has been lessened with these optics to have to open someone up and "have a look."
In light of this, I'm sure you won't be surprised to learn that, globally, nearly $50 billion a year is spent on endoscopic procedures. This is not always to treat maladies or to eradicate cancerous tissue, but sometimes to confirm that further medical attention is not needed.
Where bladder cancer is concerned--the single most-expensive cancer in North America to treat--more than $4 billion per year is spent in the U.S. alone just on bladder cancer surveillance using the current generation's imaging technology.
It is in this area that Imagin is first focusing its disruptive technology to make this surveillance--and what the patient has to endure--easier and more efficient.
When I first had the opportunity to visit at some length recently with Jim Hutchens--the C.E.O. of Imagin--I was surprised to learn how in one sense the current technology and products in the market can often fall far short in easily and accurately identifying some cancers and tumors. Indeed, Hutchens quipped that "It is shocking to me how archaic it is," meaning the relatively primitive, now, optics and lighting used to "see" bladder cancer and tumors.
Basically (and I'm going to give you the Cliff Notes version of this for now,) the white light and endoscope combination used to visualize a target area within the body--while great at identifying protruding cancerous tissue--doesn't always pick up tumors that can lay flat, let alone are underneath the bladder wall lining, etc.
Some manufacturers now produce endoscopes with a blue light filter. There is still the same white light source, but with a blue filter which--after a patient has had administered a contrasting agent that takes an hour to get into the bladder and ostensibly identify all the cancerous tissue--supposedly allows a surgeon to "see" all the cancer better.
But even here there are shortcomings. Aside from taking an hour or so for the agent to make the cancer identifiable to a surgeon, that surgeon must still manually switch from white light to blue to see the cancer area; depending on the equipment, by using two different sets of monitors.
This exacerbates a sad statistic where bladder cancer is concerned; and that is, an average of 50% of patients have a reccurrence. Better technology and a better regimen than the above would increase the chances that the job is most efficiently done right the first time.
Imagin believes it has the disruptive new technology that will change the way cancer has been detected--again, starting out with bladder cancer--for about 40 years now with relatively little in the way of advancement. In fact, so dramatically will this make current detection easier, faster and yet far more efficient at the same time, that Hutchens is confident the company can impact a big part of the market ultimately and exploit this "low hanging fruit."
Basically--and I urge you to spend some time doing your own homework on the company's web site--https://imaginmedical.com/ --
where you will learn of all this in far greater detail--Imagin's developing i/Blue Imaging System is one that "reads" what current imaging technologies via endoscopes on the market see with both white light and blue filters, yet combines that in one output.
That enables a surgeon to most effectively see on one screen (without having to go back and forth) the cancer in order to best be able to eradicate it and help reduce the chances of recurrence. Better still, the improved optics of this system and its whole process needs just 15 minutes from the beginning for a surgeon to be able to start, versus an hour now.
Just as important, this regimen allows a surgeon to see what's going on in real time. He/She is not going off of memory of what was on the last screen as he/she goes back and forth, and attempts to operate in between screen glances. Everything is right there on one output.
MOVING ON WITH DEVELOPMENT AND TOWARDS COMMERCIALIZATION
The company, Hutchens explains, expects to imminently have a "Proof of Concept" unit ready; following this, a functional model by later this Summer (Imagin presently is working on these milestones with the University of Rochester in New York and U.C.-Davis.) Ultimately it hopes to be ready to launch the i/Blue System by the time of the Spring, 2019 meeting in Chicago of the American Urology Association.
Hutchens and his team have been bolstered by both top technology and people as they move toward a market introduction. Their partner for development of the i/Blue System is Rochester-based Optel, Inc. --http://www.optel-inc.com/. The companies are working with patented information obtained from California's prestigious Lawrence Livermore Lab.
Notably, Optel is headed up by Jay Eastman. You might recognize that name, especially if you (as I) are from upstate New York and know the histories of the legendary companies that made that state their home. . .such as Eastman Kodak!
Jay--in part in working with Imagin to help bring this disruptive technology to the endoscopy market--continues the family tradition in these kinds of technologies. You can learn just a bit about Jay at https://www.photonics.com/v27/Jay_Eastman_Optel_Inc (a quick video interview) and https://newyorkphotonics.org/personnel/jay-eastman/ (some biographical information.)
Especially if both technologically and commercially successful, Hutchens' management team--as he, with extensive experience in the medical device and investment fields, as you will learn more of especially at https://imaginmedical.com/management-team-2/ where you'll similarly see an impressive board, whose members you'll learn of at https://imaginmedical.com/directors/--will move on to added applications.
Among other things I'll provide more color on as I follow up/update you on the story, I'll discuss what could be coming next!
For present purposes, Imagin seems well-positioned to use its protected Intellectual Property (specifically where i/Blue is concerned, in its process for that simultaneous/parallel acquisition of images and combining them into one) to first exploit the "low-hanging fruit" of the bladder cancer area. Indeed, a confident Hutchens mentioned to me that, "This market is really ready. . .they know they're behind."
It's no wonder that Imagin is sufficiently confident so as to already be setting up sales channels for the coming i/Blue system!
That confidence is also bolstered by the fact that--in another oversubscribed financing last year--investors included Dr. Stan Swierzewski, Chief of Surgery & Director of Urology at Holyoke Medical Center in Massachusetts, and Dr. Roger Buckley, Division Head of Urology at North York General Hospital in Toronto.
Said Dr. Swierzewski publicly about his investment decision,
"As a practicing urologist, I invested in Imagin because I have a duty and responsibility to advance any improvements in treatment and technology that will benefit my patients and save lives. Current technology is cumbersome and time consuming, taking a full hour of prep time as opposed to 10 minutes, making it less effective as a screening or follow-up tool. Bladder cancer patients are basically monitored for life with in-office cystoscopies which are not effective in differentiating between inflammation and cancer. To be safe, we perform surgery on many patients which often turns out to be negative. Imagin's i/Blue technology, given its potential speed and sensitivity, will help us assess the patient's condition more quickly and accurately and avoid unnecessary surgery. It will also make necessary surgery more successful, ultimately saving lives and reducing medical expenses. I'm confident that using the i/Blue system will become the standard of care. I look forward to the Research Study results and I cannot wait to use this technology in treating my bladder cancer patients."
Burnished by his own background with the likes of Boston Scientific on the medical side of things and with venture capital fund experience as well, Hutchens also has Imagin Medical's bank account for its clinical, development and other work topped up following its most recent--and oversubscribed--private placement that closed last month. Just after that, in issuing a quick shareholder and market update which you can read at https://imaginmedical.com/wp-content/uploads/2018/04/Press-Release-IME-Gains-Momentum-4-26-18-Final.pdf, Hutchens commented, "This is an exciting time. With proper funding and an experienced management team in place, we're confident 2018 will be a pivotal year."
Again, I'll have a bit more color on Imagin in one of the regular issues of The National Investor in the near future (together, of course, with ongoing pertinent news and the like.)
For now, I am immediately adding Imagin to my list of recommended Speculative stocks as a "BUY."
And frankly, if all goes well to commercialization, I'll along the way move Imagin to the "Growth" stock category. It's nice that, starting out, there are not the kind of risks that biotech stocks have that are developing drugs that need to go through MUCH more of a trial gauntlet. Here we have a medical device and, indeed, technology company that doesn't have as many and varied kinds of "hoops" to jump through.
To bring things to fruition here, Imagin recently announced that it had hired Pam Papineau as Director of Regulatory Affairs. Ms. Papineau has over 30 years' experience in quality and regulatory affairs with Baxter, Boston Scientific and Cogentix (Vision-Sciences), and has served as a consultant on a wide variety of devices that includes endoscopy, imaging, GI/GU, orthopedic and cardiovascular. She has successfully prepared dozens of FDA premarket submissions and European Union (EU) technical files. She will work with Hogan Lovells, Imagin's highly-regarded legal Counsel specializing in this area, as they prepare for a pre-submission meeting with the F.D.A. and follow-on activities through the regulatory approval process.
There could be great reward here to go with the risk that most any such company has. As of now, Imagin has a market cap of around C$33 million, or about US$26 million. Compare that against--first--the US$4 billion market on bladder cancer scoping alone; not to mention that--if successful here--Imagin may well be poised to proceed to disrupt the market for the other $46 billion or so of the global endoscopy market!
______________________
A QUICK "P.S." HERE -- JUST as I am sending this out, I was able to catch up with Hutchens, who is on his way to San Francisco for the American Urological Association's annual meeting for this year.
At this conference, the urologist who is currently conducting the studies at the University of Rochester Medical Center on the i/Blue System is receiving a lifetime achievement award from that body!
_________________________
A reminder . . .
HOW TO PURCHASE SHARES OF IMAGIN MEDICAL IF YOU ARE A U.S. INVESTOR USING A U.S.-BASED BROKERAGE ACCOUNT
For those of you who are not already used to buying shares of companies such as Imagin Medical that are listed primarily in Canada, I want to give you a quick and easy "tutorial." It's MUCH easier than you think, if you have never done so, to buy such companies in any U.S. brokerage account. Indeed, as I have explained in one of my investor tutorials, it's just as easy and inexpensive to buy shares in an Imagin Medical as it is to buy Apple!
Many larger Canadian and other foreign companies have primary listings on more than one major exchange. For those listed on the New York Stock Exchange or the Nasdaq as well as Toronto, you need only buy/sell using the U.S. market. Generally, there would be no reason to check prices and such on the Toronto Exchange first.
More often than not, smaller companies--for both cost and logistical reasons--do not list their shares on a major U.S. exchange. But they are still easily tradable in the U.S. via the Nasdaq's OTC Market. All you need to know is the company's symbol; unlike most U.S.-listed companies, it will always be a five-letter symbol ending with an "F."
In Imagin Medical's case, its ticker symbol in the U.S. is IMEXF, while on the Canadian Securities Exchange (CSE) it is IME. (NOTE: The CSE in Canada is the functional equivalent of the U.S. OTC market.)
The main consideration in buying shares of Canadian stocks via the OTC market is that sometimes--if you look at the OTC quote first--you are not getting as fresh and accurate a price as you would if you went to the Canadian Exchange. This is because with most, the majority of their activity is on the Canadian market where it is listed; sometimes hours can go by between trades on the OTC, if the company you're looking to buy isn't actively traded at the time. Thus, you simply need to insure, via a simple process, that you are neither overpaying for a stock when you buy it, nor getting less than you should when you sell. That is easy to accomplish.
The most reliable and current quotes for shares of companies such as Imagin are to be found first on the Canadian Exchange where they are primarily listed. Prices and volume activity are updated all through the trading day on the Toronto Exchange, TSXV and the CSE (again, the equivalent of the U.S. OTC market), just as they are on the N.Y.S.E. or Nasdaq, and are generally fresh/instantaneous.
I will use the following example to show the simple process that will normally take you LESS THAN TWO MINUTES to enter a trade to buy Imagin's stock via the OTC market in the U.S, in a typical U.S.-domiciled brokerage account:
1. First check the Canadian quote for the company, via its ticker symbol on the CSE, IME. You'll find this at the Exchange's web site, http://thecse.com/. Plug in "IME." We'll say for purposes of this lesson that the current asked price for IME's shares is C$0.275, or 27.5 cents per share in Canadian currency.
2. Next determine what that price is in U.S. currency. If you don't follow exchange rates on a daily basis, you can get a fresh picture by going to Kitco's web site, at www.kitco.com (or your own favorite one that lists currency differentials; there are many.) Near the bottom of Kitco's front page, you will find a table of various currency exchange rates. At this writing the Canadian dollar, rounded off, is worth 78.4 cents in U.S. currency.
3. Do the math as to what IME's U.S. asked (selling) price on the OTC market should be:
C 27.5 cents per share X .784 = US 21.6 cents per share.
4. Finally, enter a LIMIT ORDER to buy the number of shares of Imagin you want in your U.S. brokerage account at or very near that price. Personally, I would first start with that US 21.6 cents per share. If the order doesn't fill right away, bump it up by a tenth of a cent once or twice until it does (these days, most online brokers will allow you to use tenths of a cent in pricing.)You would use the company's 5-letter symbol, which is IMEXF.
It's that simple! And, of course, you would do much the same thing when it was time to sell some of your holdings. But in the case of a sale, you would focus on the bid price listed on the CSE's site for the company in question.
As always, if you have any comments or questions, let me know!
All the best,
Chris Temple -- Editor/Publisher
The National Investor
https://nationalinvestor.com/
$BKPPF A MUST read....Blok Conference call Transcript
Smart Investors Read Between the Lines & Connect The Dots
http://valueinvestor.com/2018/05/11/block-one-capital-bkppf-blok-v-conference-call/
3 Blockchain Stocks To Have On Your Radar
https://medium.com/stock-market-source/3-blockchain-stocks-to-have-on-your-radar-f744a482bd7b
The call was amazing. Great thing we know now is BLOK has nothing to do with Bitcoin price.
$BKPPF Blok Conference call Transcript
Smart Investors Read Between the Lines & Connect The Dots
http://valueinvestor.com/2018/05/11/block-one-capital-bkppf-blok-v-conference-call/
$BKKPF BLOCK ONE ANNOUNCES CORPORATE UPDATE CONFERENCE CALL WITH CEO SOTHI THILLAIRAJAH
Sothi Thillairajah, chief executive officer of Block One Capital Inc., will hold a conference call to discuss advancements made with its current investments and also update shareholders on the company's outlook going forward.
Shareholders and interested parties are invited to participate in the conference call. The call will start promptly at 4:30 p.m. EST on Thursday, May 10, 2018. The dial-in number for the call is 712-775-7031. The meeting ID number is 576-591-822.
We seek Safe Harbor.
https://www.stockwatch.com/News/Item.aspx?bid=Z-C%3aBLOK-2606330&symbol=BLOK®ion=C
$BGGWF Hilltop Cybersecurity Announces DTC Eligibility
2018-05-03 14:28 ET - News Release
KELOWNA, British Columbia, May 03, 2018 (GLOBE NEWSWIRE) -- Hilltop Cybersecurity Inc, (“Hilltop” or the “Company”) (CSE:CYBX) (OTC:BGGWF), is pleased to announce that it has been made eligible for Depository Trust Company (“DTC”) electronic settlement and transfer of its common shares in the United States under the OTC symbol BGGWF.
The DTC is a subsidiary of the Depository Trust & Clearing Corporation that manages the electronic clearing and settlement of publicly traded companies. Securities that are eligible to be electronically cleared and settled through the DTC are considered "DTC eligible." This electronic method of clearing securities speeds up the receipt of stock and cash, and thus accelerates the settlement process for investors.
For further information, please contact:
Hilltop Cybersecurity
info@hilltopcybersecurity.com
778-484-8028
About Hilltop Cybersecurity
Hilltop Cybersecurity (CSE:CYBX) (OTC:BGGWF) is a cybersecurity and cryptocurrency security specialist. The Company has developed a unique, patented, cybersecurity platform, designed to protect businesses from external and internal cyber attack, and has also patented its biometric security solution for crypto-currencies.
Love news $BKPPF is teh real deal, here's why:
As of today Blok has:
* Cash : $4,238,338
* Investents: $7,672,551
* More cash : from $1 PP that just closed: : $2,000,000
* 8.9 Million KASH shares, (7.5% of the enire float,/company ) let's remember KASH did a bought deal of $29.7 Million for 14 million shares $2.45/share back in Jan
Giving them access not just to the mining side but also their Blockchain TAX NODE40 NODE40 Balance is a robust cryptocurrency reporting software that integrates directly with certain major cryptocurrency exchanges.they paid $8 Million for...
* SHOPIN ICO: Block One Capital Announced USD $750,000 Allocation in Oversubscribed Private Presale Token of Shopin = 13 million coins !!
https://tokensale.shopin.com/
Winner of Best ICO at the North American Bitcoin Conference and the Winner of Best ICO at the CoinAgenda Bitcoin/Cryptocurrency investing conference.
You guys jave any clue what this coin will open at $$$$$...
* OMMAT: 40% of London, UK Based Rainforest Protection Fintech Company.
OMMAT is a blockchain based, patented fintech solution aimed at democratizing the purchase and protection of natural capital such as rainforests. OMMAT has previously been featured in Forbes magazine: http://bit.ly/2DbBW5B
* FINZAT
Ahh the mother load here, this is a company maker on it's own...just wait...
Finzat, the New York, USA based mortgage blockchain company, Finzat’s business proposition is to streamline and digitize the approximate ten trillion dollar United States mortgage market
***(Now did you read the news today.....)
1) Finzat has opened a dialogue with a nationally recognized provider of risk management software and consulting services to over 120 institutional clients and several housing GSEs.
2) Finzat is scheduled to open discussions early in May 2018 with a European headquartered international financial management company currently servicing hundreds of institutional clients around the globe.
News ! Big things going to happen...
https://finance.yahoo.com/news/block-one-capital-provides-finzat-070500464.html
Block One Capital Provides Update on Finzat
ANCOUVER, British Columbia, May 01, 2018 (GLOBE NEWSWIRE) -- Block One Capital Inc. (BLOK.V) (BKPPF) (ES3.F) (the “Company” or “Block One”), an investment company focused on high growth opportunities in the blockchain sector, is pleased to provide the following corporate update regarding progress made by Finzat since its previous management and support team changes. As previously announced, Block One holds approximately a 40% interest in Finzat.
Finzat continues to make positive strides in developing relationships among key participants in the US residential mortgage market. Recent talks with a Housing Government Sponsored Enterprise (GSE) have served to highlight opportunities for a synergistic partnership whereby Finzat would bring benefits of blockchain applications to mature, well-established business lines. Senior level discussions continue with a view toward designing application prototypes within the next few months.
Furthermore, Finzat has opened a dialogue with a nationally recognized provider of risk management software and consulting services to over 120 institutional clients and several housing GSEs. A framework for a formal arrangement between the two parties is currently being formulated.
In addition, Finzat is scheduled to open discussions early in May 2018 with a European headquartered international financial management company currently servicing hundreds of institutional clients around the globe. Among the firm’s activities are those that involve the assembly and dissemination of sensitive personal data, offering potential for Finzat and blockchain technology.
For more information on Block One please visit the Company’s website at www.blockonecap.com.
“Sothi Thillairajah”
Chief Executive Officer
Sudden Push for Improved Blockchain Technology Jumps to the Forefront
https://www.prnewswire.com/news-releases/sudden-push-for-improved-blockchain-technology-jumps-to-the-forefront-680929041.html
3 Blockchain Stocks Ready To Ride The Next Tech Wave
https://medium.com/@MrSmallCap/3-crypto-market-catalysts-are-making-moves-a6b8bd31174e
$BKPPF Just closed another PP at $1
In the event that the Shares trade at a closing price of greater than $2.50 per Share for ten (10) consecutive trading days, the Company may accelerate the expiry date of the Warrants to expire on the 30th day after the date on which such notice is given by Block One.
https://www.stockwatch.com/News/Item.aspx?bid=Z-C%3aBLOK-2598653&symbol=BLOK®ion=C
https://www.stockwatch.com/News/Item.aspx?bid=Z-C%3aIME-2598643&symbol=IME®ion=C
Imagin Gains Momentum; Positive Progress in Research Study
2018-04-26 08:30 ET - News Release
VANCOUVER, British Columbia and BOSTON, April 26, 2018 (GLOBE NEWSWIRE) -- Imagin Medical (CSE:IME) (OTC PINK:IMEXF) (Frankfurt & Stuttgart Symbol:DPD2) (the “Company”) is providing the following update on the Company’s current activities.
The recent closing of a Private Placement for approximately $4,000,000 reinforces Imagin’s financial runway, enabling the Company to progress through the next critical steps toward product commercialization. Imagin’s management team has been strengthened with the recent appointments of a new CFO and Director of Regulatory Affairs who add the essential experience and knowledge base in the medical device industry to drive the Company through several paths concurrently.
To date, five subjects have been evaluated using the i/Blue System. Given that this study is the i/Blue system’s initial use in a human bladder, approximately two weeks have been allowed between procedures for the development team to assess performance and to make hardware improvements, such as lenses and filters, as well as software adjustments. More subjects will be scheduled for evaluation, and further updates will be issued. The data and knowledge Imagin is acquiring is essential in refining the images that the company believes will lead to optimal performance.
Simultaneously, the Company continues to work with Optel, Inc. on the product redesign for future clinical trials and commercialization. The miniaturization process will add significant imaging capability and lower the actual cost of the product. In addition, documentation for federal regulatory approval continues in anticipation of meetings expected to take place during the summer months.
“This is an exciting time. With proper funding and an experienced management team in place, we’re confident 2018 will be a pivotal year,” said Jim Hutchens, Imagin’s President and CEO.
About Imagin Medical
Imagin Medical is developing imaging solutions for the early detection of cancer during minimally invasive surgeries. The Company believes it will radically improve the way physicians detect cancer. Imagin’s initial target market is bladder cancer, a major cancer worldwide, the sixth most prevalent in the U.S., and the most costly cancer to treat due to a greater than 50% recurrence rate. Developed at the Lawrence Livermore National Laboratory, this advanced, ultrasensitive imaging technology is based upon improved optical designs and advanced light sensors. Learn more at www.imaginmedical.com.
For further information, contact:
Jim Hutchens, President & CEO
Telephone: 617-571-6006
Email: jhutchens@imaginmedical.com